James Patrick McCauley Jr., J.D., M.B.A. Net Worth

The estimated Net Worth of Patrick Mc Cauley is at least $616 mil dollars as of 31 January 2020. Mr Cauley owns over 5,000 units of Mannkind Corp stock worth over $615,654 and over the last 7 years he sold MNKD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr A MNKD stock SEC Form 4 insiders trading

Mr has made over 4 trades of the Mannkind Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of MNKD stock worth $4,750 on 31 January 2020.

The largest trade he's ever made was buying 5,000 units of Mannkind Corp stock on 31 January 2020 worth over $4,750. On average, Mr trades about 1,818 units every 50 days since 2018. As of 31 January 2020 he still owns at least 100,433 units of Mannkind Corp stock.

You can see the complete history of Mr Cauley stock trades at the bottom of the page.

Mr. James Patrick McCauley Jr., J.D., M.B.A. biography

James Patrick McCauley Jr., J.D., M.B.A. is the Chief Commercial Officer at Mannkind Corp.

How old is Mr A?

Mr A is 55, he's been the Chief Commercial Officer of Mannkind Corp since . There are 12 older and 10 younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.

What's Mr A's mailing address?

Patrick's mailing address filed with the SEC is 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91362.

Insiders trading at Mannkind Corp

Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens, eDavid Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.

What does Mannkind Corp do?

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.

Complete history of Mr Cauley stock trades at Mannkind Corp

Mannkind Corp executives and stock owners

Mannkind Corp executives and other stock owners filed with the SEC include:

• Michael Castagna,
  Chief Executive Officer, Director
• Dr. Michael E. Castagna Pharm.D.,
  CEO & Director
• Stuart Tross,
  Chief People and Workplace Officer
• David Thomson,
  Executive Vice President, General Counsel, Secretary
• Dr. Michael E. Castagna,
  CEO & Director
• Steven Binder,
  Chief Financial Officer
• Dr. David B. Thomson,
  Exec. VP, Gen. Counsel & Sec.
• Joseph Kocinsky,
  Chief Technology Officer
• Steven B. Binder,
  Chief Financial Officer
• Joseph Kocinsky M.B.A., M.S.,
  Chief Technology Officer
• Dr. Stuart A. Tross,
  Chief People & Workplace Officer
• Rosabel Alinaya,
  Vice President of Investor Relations, Interim Corporate Controller, Treasurer
• Christine Mundkur,
  Independent Director
• Kent Kresa,
  Independent Chairman of the Board
• Ronald Consiglio,
  Independent Director
• Michael Friedman,
  Independent Director
• James Shannon,
  Independent Director
• Kevin Kaiserman,
  Vice President - Medical Affairs and Safety
• Jennifer Grancio,
  Independent Director
• Anthony Hooper,
  Independent Director
• Alejandro Galindo M.B.A., M.S.,
  Chief Commercial Officer
• James Patrick McCauley Jr., J.D., M.B.A.,
  Chief Commercial Officer
• John F. Bedard,
  Sr. VP of Worldwide Regulatory Affairs
• Rosabel Realica Alinaya,
  VP of Investor Relations & Treasury
• Thomas Hofmann M.D., Ph.D.,
  Chief Scientific Officer
• Matthew J Pfeffer,
  Corporate VP and CFO
• Henry L Nordhoff,
  Director
• David Mac Callum,
  Director
• Raymond W. Urbanski,
  Corp VP, CMO
• David M Kendall,
  Chief Medical Officer
• Elizabeth Garrett Ingram,
  Chief Marketing Officer
• Courtney Barton,
  Chief Compl & Privacy Officer
• Patrick Mc Cauley,
  Chief Commercial Officer
• John R. Riesenberger,
  VP & Chief Commercial Officer
• Richard L Anderson,
  VP & CFO
• Heather Hay Murren,
  Director
• Kathleen Connell,
  Director
• Llew Keltner,
  Director
• Dan Burns,
  VP & President, MKBP
• W Wendell Cheatham,
  VP, Medical & Reg Affairs
• Juergen Martens,
  Corporate VP
• Hakan Edstrom,
  President & COO
• Alfred E Mann,
  Chairman & CEO
• Diane Palumbo,
  Vice President, Human Resource
• Abraham E Cohen,
  Director
• Peter C Richardson,
  Chief Scientific Officer
• Lauren M Sabella,
  EVP Chief Operating Officer
• Alejandro Galindo,
  EVP Endocrine Business Unit
• Burkhard Blank,
  EVP Chief Medical Officer
• Sanjay R Singh,
  EVP Technical Operations
• Christopher B Prentiss,
  Chief Financial Officer
• Sabrina Kay,